BNP Paribas Exane upgraded Novo Nordisk (NVO) to Neutral from Underperform with a $54 price target The firm sees a more balanced risk/reward, saying Novo’s “reality” is now better reflected in the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Analysts Reaffirm Buy Ratings on Eli Lilly After Stock Suffers Worst Decline Since 2008
- Mixed options sentiment in Novo Nordisk with shares down 1.85%
- ‘Time to Double Down,’ Says Top Investor About Novo Nordisk Stock
- How Wall Street Missed the Bigger Picture on Novo Nordisk Stock (NVO)
- Sector Spotlight: Trump administration seeks hometown discount from Big Pharma